Medtronic (NYSE:MDT) Upgraded at Wall Street Zen

Medtronic (NYSE:MDT) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Other research analysts have also issued reports about the stock. UBS Group raised their price objective on shares of Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Leerink Partners set a $120.00 price target on shares of Medtronic and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Daiwa Capital Markets lifted their price target on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Truist Financial lowered their price objective on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a research note on Thursday. Finally, Cowen restated a “buy” rating on shares of Medtronic in a report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $109.94.

Medtronic Trading Up 0.2%

Shares of Medtronic stock opened at $98.63 on Friday. The stock has a market capitalization of $126.45 billion, a PE ratio of 26.59, a price-to-earnings-growth ratio of 2.59 and a beta of 0.71. Medtronic has a 52 week low of $79.29 and a 52 week high of $106.33. The stock has a 50 day moving average price of $97.38 and a two-hundred day moving average price of $93.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same period last year, the business earned $1.26 EPS. Medtronic’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts anticipate that Medtronic will post 5.46 earnings per share for the current fiscal year.

Institutional Trading of Medtronic

Institutional investors and hedge funds have recently modified their holdings of the business. Advisors Management Group Inc. ADV grew its stake in Medtronic by 1.4% in the 3rd quarter. Advisors Management Group Inc. ADV now owns 52,549 shares of the medical technology company’s stock valued at $5,005,000 after purchasing an additional 704 shares during the period. Hudson Bay Capital Management LP raised its stake in shares of Medtronic by 134.5% during the 3rd quarter. Hudson Bay Capital Management LP now owns 25,016 shares of the medical technology company’s stock worth $2,383,000 after purchasing an additional 97,432 shares during the period. Innova Wealth Partners purchased a new position in shares of Medtronic in the 3rd quarter worth about $210,000. Tevis Investment Management grew its position in Medtronic by 1.8% during the third quarter. Tevis Investment Management now owns 53,510 shares of the medical technology company’s stock valued at $5,134,000 after buying an additional 958 shares during the period. Finally, Groupama Asset Managment grew its position in Medtronic by 62.9% during the third quarter. Groupama Asset Managment now owns 57,642 shares of the medical technology company’s stock valued at $5,490,000 after buying an additional 22,255 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic filed an S-1 to take its Diabetes unit, MiniMed, public — the preferred separation path is an IPO followed by a split-off. Management says the move is part of a planned separation aimed at creating two focused companies, which could unlock value and provide strategic clarity. Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed
• Positive Sentiment: Regulatory and product progress: Medtronic (and peers) secured FDA nods for liquid embolic systems — a reminder the company continues to advance therapeutic devices that can support organic growth beyond the diabetes separation. Medtronic, J&J MedTech both get FDA nods for liquid embolic systems
• Neutral Sentiment: Ownership and structure details may limit immediate financial impact — media reports note Medtronic expects to retain majority voting control (reported at least ~80.1% of voting stock), suggesting the IPO could be more about strategic focus and value crystallization than a full divestiture. Medtronic Spin-Off MiniMed Files for IPO
• Neutral Sentiment: Analyst stances remain cautious: some firms (e.g., Robert W. Baird) are maintaining “hold” ratings, reflecting mixed near-term views even as the strategic move unfolds. Robert W. Baird Remains a Hold on Medtronic (MDT)
• Negative Sentiment: Price-target trim: Truist cut its MDT price target modestly (from $110 to $107) and kept a “hold” rating, a sign some analysts see limited near-term upside despite the strategic separation. This analyst action could cap momentum until clearer financials for MiniMed and separation mechanics are disclosed. Medtronic price target lowered to $107 from $110 at Truist

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).